Key PointsAmong 259 patients receiving CAR T cells for lymphoma, 26% had weight loss, defined as >5% reduction in body mass index in the preceding 3 mon
Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.
David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.
LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.
Abstract. The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic
Key Points. No significant survival benefit with salvage autologous transplant versus lenalidomide/dexamethasone in relapsed and/or refractory myelomaTime
Key Points. Induction therapy with IsaKRD in the MIDAS study yielded the highest pre-transplant MRD-negativity rates ever reported in TE NDMM patientsThe f
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
CMG901 showed a manageable safety profile and had promising antitumour activity in patients with advanced gastric or gastro-oesophageal junction cancer.
Annals of Surgical Oncology – The association of hospital market competition, financial costs, and quality of oncologic care has not been well-defined. This study sought…
The assumption that thermal ablation should be reserved for unresectable colorectal liver metastases requires re-evaluation and the preferred treatment should be individualised and based on…
